Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.54 |
| ▸ | UCHL1 | P09936 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075142 | 0.87 | USP30 (0.42) | USP30UCHL1 | |
| SCHEMBL17775472 | 0.82 | USP30 (0.54) | USP30UCHL1NPC1MEN1KMT2A | |
| SCHEMBL19364511 | 0.82 | USP30 (0.54) | USP30UCHL1NPC1MEN1KMT2A | |
| SCHEMBL2074562 | 0.80 | USP30 (0.44) | USP30UCHL1NPC1HSD17B10 | |
| SCHEMBL749562 | 0.76 | UCHL1 (0.45) | USP30UCHL1NPC1MEN1KMT2A | |
| SCHEMBL2072188 | 0.74 | CTSC (0.53) | USP30NPC1MEN1KMT2ALMNA | |
| SCHEMBL2072191 | 0.74 | CTSC (0.53) | USP30NPC1MEN1KMT2ALMNA | |
| SCHEMBL10790818 | 0.74 | KMT2A (0.50) | USP30UCHL1NPC1MEN1KMT2A | |
| SCHEMBL10790832 | 0.74 | KMT2A (0.50) | USP30UCHL1NPC1MEN1KMT2A | |
| SCHEMBL750224 | 0.74 | KMT2A (0.47) | USP30UCHL1NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | USP30 3892/4885UCHL1 4197/4885NPC1 628/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | USP30 3892/4885UCHL1 4197/4885NPC1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.